Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity: 2 US clinical trials tracked, none currently recruiting.
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sanjiv Sam Gambhir, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-esthesioneuroblastoma-of-the-paranasal-sinus-and-nasal-cavity
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Sanjiv Sam Gambhir
NCT01806675
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Fox Chase Cancer Center
NCT01637194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sanjiv Sam Gambhir sponsors the most Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity trials on record, review their full trial history before evaluating a specific study. See Sanjiv Sam Gambhir's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity condition card totals 2 registered trials; most-linked intervention 18F-FPPRGD2; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.